PT-141 key research findings span more than three decades of peptide science, from early observations about melanocyte-stimulating hormones in the 1960s to a first-in-class FDA approval in 2019. Few research compounds have a paper trail as long and as eventful as PT-141, the investigational name for bremelanotide — a synthetic cyclic heptapeptide developed from the melanotan family of α-MSH analogues. This article rounds up the most-cited PT-141 key research findings as reported in published studies, trial records, and regulatory documents: the compound’s origins, what pharmacology research established about its structure and receptor activity, what the clinical trial program found (and did not find), and where the science currently stands. Everything here is framed for laboratory research use — the PT-141 key research findings below describe published science, not guidance for any use outside a research setting.
Research-use-only disclaimer: PT-141 (bremelanotide) is discussed here strictly as a research subject. All products on this site are sold strictly for laboratory research use. This article is an educational summary of published findings. It contains no medical advice, no dosage information, no administration instructions, and no claims about human outcomes.
PT-141 Key Research Findings at a Glance
Before the detailed tour, here is the condensed version of the PT-141 key research findings most often cited in the literature. Each row is expanded in the sections that follow.
| Finding | What the literature shows |
|---|---|
| Chemical identity | PT-141 is bremelanotide, a cyclic heptapeptide lactam analogue of α-melanocyte-stimulating hormone (α-MSH) |
| Mechanism class | Non-selective melanocortin receptor agonist (MC1–MC5, except MC2), acting primarily at MC3 and MC4 receptors |
| Origin | Developed by Palatin Technologies as a metabolite of melanotan II; rooted in University of Arizona α-MSH research |
| Intranasal program | Phase II intranasal trials were halted by the FDA in 2007 over blood-pressure signals; the format was discontinued in 2008 |
| Pivotal trials | Two Phase III RECONNECT trials (about 1,200 participants) met co-primary endpoints on desire and distress; results published in 2019 |
| Regulatory outcome | FDA approval in June 2019 as Vyleesi for acquired, generalized HSDD in premenopausal women; designated first-in-class |
| Effect sizes | Independent researchers have described the demonstrated benefits as modest |
| Safety signals | Nausea most frequent; flushing, headache, injection-site reactions; transient blood-pressure increase; possible hyperpigmentation with frequent use |
Why this roundup matters for researchers: PT-141 is one of the rare research peptides with a complete public arc — discovery chemistry, failed delivery formats, a reformulated trial program, published Phase III data, and a regulatory decision. That makes the PT-141 key research findings a useful case study in how peptide science actually progresses: rarely in a straight line.
How PT-141 Entered the Research Literature
The PT-141 key research findings begin long before the compound had a name. The story starts with α-MSH itself: studies in the early 1960s reported that administering α-MSH caused sexual arousal in rats, planting the first flag that the melanocortin system might intersect with sexual behavior. That observation sat largely dormant until the 1980s, when scientists at the University of Arizona began developing α-MSH analogues as potential sunless tanning agents — work that produced the peptides later named melanotan-I and melanotan-II.
The pivot from tanning to sexual function came through an accident that is now part of peptide-research lore: during very early self-experimentation with melanotan II, a researcher administered twice the intended amount and experienced a prolonged erection along with nausea and vomiting. That unexpected signal redirected the entire program. Melanotan II was licensed to Palatin Technologies for development as a sexual-dysfunction agent; Palatin halted melanotan II development in 2000 and instead synthesized and patented bremelanotide — a likely metabolite of melanotan II differing by a hydroxyl group where melanotan II carries an amide.
PT-141 Research Timeline
- Early 1960s — α-MSH administration reported to cause sexual arousal in rats, linking the melanocortin system to sexual behavior in the research literature.
- 1980s — University of Arizona scientists develop α-MSH analogues (melanotan-I, melanotan-II) as candidate sunless tanning agents.
- 2000 — Palatin Technologies stops melanotan II development and begins developing bremelanotide (PT-141), a melanotan II metabolite.
- 2004 — Palatin signs a co-development agreement with King Pharmaceuticals for bremelanotide in the US.
- 2007 — The FDA halts Phase II intranasal bremelanotide trials in female sexual dysfunction and male erectile dysfunction over increased blood pressure in subjects; intranasal development ends in 2008.
- Late 2014 — Two Phase III trials (RECONNECT) launch using a subcutaneous autoinjector formulation in female sexual dysfunction.
- November 2016 — Phase III results announced; the RECONNECT data cover approximately 1,200 participants.
- June 2018 — The New Drug Application is accepted by the FDA.
- June 21, 2019 — The FDA approves bremelanotide as Vyleesi for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, designating it a first-in-class medication. The Phase III data are published in Obstetrics & Gynecology later that year.
That timeline is one of the most instructive PT-141 key research findings in itself: a compound can survive the death of its original delivery format and still reach approval after reformulation. Researchers studying peptide delivery formats face this pattern often — our companion overview of Selank nasal spray research and Semax nasal spray research shows how format questions keep resurfacing across the peptide literature.
What the Pharmacology Research Established
The chemistry and pharmacology are among the most solidly documented PT-141 key research findings. Structurally, bremelanotide is a cyclic heptapeptide lactam analogue of α-MSH, with the amino acid sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. The cyclic structure matters: cyclization is a classic medicinal-chemistry strategy to improve a peptide’s stability relative to its linear parent, and it is part of why PT-141 became a more tractable research compound than the melanotan II it derived from.
Pharmacodynamically, published research characterizes bremelanotide as a non-selective agonist of the melanocortin receptors — MC1 through MC5, with the exception of MC2 (the ACTH receptor) — acting primarily as an MC3 and MC4 receptor agonist. The MC4 receptor is the focal point of most mechanistic discussion: central melanocortin signaling, particularly through MC4R, had been implicated in sexual function in animal models, which is why a melanocortin agonist became a candidate in this research area at all. For context on the receptor family, see the melanocortin receptor overview on Wikipedia.
Pharmacokinetic findings reported in the literature include near-complete bioavailability via subcutaneous administration, maximal plasma levels occurring within roughly half an hour to an hour, an elimination half-life of about 2.7 hours, metabolism via hydrolysis of the peptide bonds, and excretion split between urine and feces. These are standard characterization data — the kind of profile researchers expect to see established for any peptide that reaches late-stage trials — and they round out the core PT-141 key research findings on the compound’s behavior in the body.
Central vs. peripheral action: One frequently cited distinction in the PT-141 key research findings is that bremelanotide’s proposed site of action is central (melanocortin receptors in the brain) rather than peripheral vascular tissue — the opposite of how PDE5 inhibitors work. That is also why the FDA noted that the mechanism by which it improves sexual desire and related distress is officially listed as unknown: receptor binding is established; the downstream behavioral mechanism is not.
PT-141 Key Research Findings From the Clinical Trial Record
The trial record holds some of the most-cited PT-141 key research findings — and the most instructive failures. Palatin’s Phase II program tested an intranasal formulation in both female sexual dysfunction and male erectile dysfunction (four trials in ED, the last a Phase IIb published in 2008). In 2007 the FDA halted these trials because subjects showed increased blood pressure, and Palatin discontinued the intranasal formulation in 2008. For researchers, this is a landmark data point: a delivery format can fail on cardiovascular signals even when the underlying compound remains viable.
The program was then reformulated around subcutaneous delivery via autoinjector. A Phase II dose-finding trial in female sexual dysfunction showed promise at the highest dose with only transient blood-pressure signs, and two Phase III trials were launched at the end of 2014. In November 2016, Palatin announced the RECONNECT results: in both randomized, double-blind, placebo-controlled trials, bremelanotide met the pre-specified co-primary efficacy endpoints — improvement in desire and reduction in associated distress, measured by validated patient-reported outcome instruments. The data, covering approximately 1,200 women, were published in Obstetrics & Gynecology in 2019 and formed the basis of the FDA approval. Trial-focused readers can browse indexed bremelanotide studies via PubMed.
Honest reporting of the PT-141 key research findings requires the counterpoint: independent researchers questioned the relevance and validity of the rating scales used and the size of the drug’s effects, concluding benefits may be only modest. The FDA’s own approval materials describe a responder analysis in which about a quarter of treated patients showed a defined improvement in desire scores versus roughly a sixth on placebo. That gap — statistically significant, clinically debated — is the defining tension of the PT-141 trial literature, and any serious roundup of PT-141 key research findings has to include it.
PT-141 Key Research Findings on the Safety Profile
Safety data are part of every PT-141 key research findings summary because the signals shaped the program’s history. Across the two Phase III trials, the most frequently reported adverse events were nausea (the dominant signal, affecting a large share of treated subjects), flushing, injection-site reactions, headache, and vomiting. Most were described as transient and mild to moderate in intensity. The blood-pressure story persisted in milder form: bremelanotide can cause a temporary increase in blood pressure and a decrease in heart rate after administration, which is why uncontrolled hypertension or cardiovascular disease are listed as contraindications. With frequent use, skin discoloration (hyperpigmentation of the face, gums, or breasts) was reported, and it may not fully resolve after stopping. Animal studies, even at high exposures, found no negative effect on fertility — another data point researchers cite from the published record.
What the safety findings mean in research terms: The PT-141 key research findings on safety illustrate a common late-stage pattern — a compound’s efficacy case and its tolerability case are judged separately, and a drug can be approved with a prominent side-effect profile (here, nausea) as long as the signals are characterized and manageable within labeled use. For laboratory researchers, the lesson is methodological: adverse-event characterization is part of the science, not an afterthought.
What the Research Did Not Establish
A complete roundup of PT-141 key research findings should also mark the boundaries. The mechanism by which bremelanotide improves sexual desire and related distress remains officially unknown — receptor pharmacology is mapped, but the link from MC3/MC4 agonism to the behavioral outcome is not fully explained. The compound was not approved for men: the male erectile-dysfunction program ended with the intranasal formulation and was never resurrected. And while the approved indication is acquired, generalized HSDD in premenopausal women without an underlying medical, psychiatric, or relationship cause, the literature contains active debate about whether the measured benefits are clinically meaningful. For a head-to-head research-comparison format applied to other peptides, see our Selank vs Semax research comparison.
Key Takeaways — PT-141 Key Research Findings
- PT-141 (bremelanotide) is a cyclic heptapeptide α-MSH analogue and primarily an MC3/MC4 melanocortin receptor agonist, developed by Palatin Technologies from melanotan II.
- The intranasal development program was halted by the FDA in 2007 over blood-pressure signals — a landmark finding about delivery-format risk in peptide research.
- Two Phase III RECONNECT trials (~1,200 participants) met co-primary endpoints on desire and distress, leading to FDA approval on June 21, 2019 as Vyleesi for acquired, generalized HSDD in premenopausal women.
- Independent researchers have described the demonstrated benefits as modest — the most debated of the PT-141 key research findings.
- The mechanism linking melanocortin agonism to the behavioral outcome remains officially unknown, and the compound was never approved for men.
- All of the above describes published research. Our research-vial listings, such as Semax 10mg and Selank 10mg, are supplied strictly for laboratory research use.
Conclusion
The PT-141 key research findings tell a story that is equal parts chemistry, clinical science, and regulatory history. A tanning-research offshoot became a melanocortin agonist; an intranasal program failed on cardiovascular signals; a reformulated injectable program produced two positive Phase III trials; and in 2019 the compound earned a first-in-class FDA approval for a narrowly defined indication — with effect sizes that researchers still debate. For anyone studying how research peptides move from bench to bedside, the PT-141 key research findings are one of the most complete public case studies available: the successes are published, the failures are documented, and the open questions are clearly marked. That is what makes them worth rounding up — and worth reading in the primary literature rather than in summary alone.
PT-141 Key Research Findings: Frequently Asked Questions
What is PT-141 in research terms?
PT-141 is the investigational name for bremelanotide, a synthetic cyclic heptapeptide lactam analogue of α-melanocyte-stimulating hormone (α-MSH). Published research characterizes it as a melanocortin receptor agonist acting primarily at MC3 and MC4 receptors. It was developed by Palatin Technologies as a metabolite of melanotan II.
What did the Phase III trials find?
The two RECONNECT trials, covering approximately 1,200 participants, met their pre-specified co-primary endpoints: improvement in sexual desire and reduction in associated distress, measured by validated patient-reported instruments. The data were published in Obstetrics & Gynecology in 2019. Independent researchers have described the demonstrated benefits as modest.
Why was the intranasal PT-141 program stopped?
The FDA halted Phase II intranasal bremelanotide trials in 2007 because clinical trial subjects showed increased blood pressure. Palatin discontinued the intranasal formulation in 2008 and reformulated the compound for subcutaneous delivery via autoinjector.
When was PT-141 approved, and for what?
The FDA approved bremelanotide (brand name Vyleesi) on June 21, 2019, for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women whose low desire is not caused by a medical, psychiatric, or relationship problem. The FDA designated it a first-in-class medication.
Is PT-141 approved for men?
No. The male erectile-dysfunction trial program ended with the discontinued intranasal formulation and was never carried through to approval. The only approved indication is in premenopausal women with HSDD.
Where can researchers read the primary PT-141 literature?
Indexed studies are searchable on PubMed under “bremelanotide,” and the compound’s chemistry and history are summarized on Wikipedia’s bremelanotide page. Laboratory researchers sourcing reference material should use suppliers explicit about research-use-only status.
